Abhilash Deo - Publications
Affiliations: | 2015-2021 | Imaging Cell Signalling and Therapeutics Lab | ACTREC, Mumbai |
Year | Citation | Score | |||
---|---|---|---|---|---|
2023 | Benguigui M, Cooper TJ, Kalkar P, Schif-Zuck S, Halaban R, Bacchiocchi A, Kamer I, Deo A, Manobla B, Menachem R, Haj-Shomaly J, Vorontsova A, Raviv Z, Buxbaum C, Christopoulos P, et al. Interferon-stimulated neutrophils as a predictor of immunotherapy response. Cancer Cell. PMID 38181798 DOI: 10.1016/j.ccell.2023.12.005 | 0.342 | |||
2023 | Deo A, Sleeman JP, Shaked Y. The role of host response to chemotherapy: resistance, metastasis and clinical implications. Clinical & Experimental Metastasis. PMID 37999904 DOI: 10.1007/s10585-023-10243-5 | 0.387 | |||
2021 | Deo AN, Thorat R, Dhadve AC, De A, Rekhi B, Ray P. IGF1R-α6 integrin-S100A4 network governs the organ-specific metastasis of chemoresistant epithelial ovarian cancer cells. Biochimica Et Biophysica Acta. Molecular Basis of Disease. 1868: 166282. PMID 34600083 DOI: 10.1016/j.bbadis.2021.166282 | 0.333 | |||
2020 | Deo A, Mukherjee S, Rekhi B, Ray P. Subtype specific biomarkers associated with chemoresistance in epithelial ovarian cancer. Indian Journal of Pathology & Microbiology. 63: S64-S69. PMID 32108633 DOI: 10.4103/IJPM.IJPM_872_19 | 0.535 | |||
2019 | Deo A, Chaudhury S, Kannan S, Rekhi B, Maheshwari A, Gupta S, Ray P. IGF1R predicts better survival in high-grade serous epithelial ovarian cancer patients and correlates with hCtr1 levels. Biomarkers in Medicine. PMID 31140856 DOI: 10.2217/bmm-2018-0311 | 0.482 | |||
Show low-probability matches. |